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Purpose
To estimate the frequency of pathologic complete
response (pCR) after neoadjuvant treatment with cisplatin
chemotherapy in women with breast cancer and who are
BRCA1 mutation carriers.
Patients and Methods
107 women with BRCA1 mutation and affected with
breast cancer, who presented with stage I to III breast
cancer between December 2006 and June 2014 received
treatment with cisplatin 75 mg/m2 every three weeks for
four cycles, followed by mastectomy and conventional
chemotherapy (AC). Information on clinical stage, grade,
hormone receptor status and HER2 status was collected
prior to treatment. Review of surgical samples was done in
order to determine the pathologic complete response.
Results
107 patients were included in the study. 93 patients were
treated for first primary breast cancer and 14 patients had
previously received treatment for a prior cancer. A patho-
logic complete response was observed in 65 of the 107
patients (61%).
Conclusions
In a high proportion of patients with BRCA1-associated
breast cancer platinum-based chemotherapy is an effective
method of treatment.
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